Sol-Gel Coatings Companies

June 2023

The signing of exclusive licence agreements for TWYNEO and EPSOLAY for the Canadian market was announced today by Sol-Gel Technologies Ltd., an Israeli dermatology company, and Searchlight Pharma Inc., a private specialty pharmaceutical company in Canada. Sol-Gel is the creator of TWYNEO and EPSOLAY, two cutting-edge, widely available dermatology products. The U.S. launch of both products occurred recently, and Searchlight will commercialise in Canada for a fifteen-year period that can be extended for additional five-year periods.

For the treatment of acne vulgaris in adults and paediatric patients nine years of age and older, TWYNEO (tretinoin, 0.1% and benzoyl peroxide, 3% cream) is used. Adults with rosacea who have inflammatory lesions are treated with EPSOLAY (benzoyl peroxide, 5% cream).

Under the terms of the agreement, Sol-Gel will be compensated with potential upfront payments of up to $11 million as well as regulatory and sales milestones for the combined use of both drugs. Furthermore, Sol-Gel will be eligible to receive royalty percentages ranging from low double digits to high teens on all Canadian net sales.

With assistance from Sol-Gel, Searchlight will be in charge of securing and upholding any regulatory approvals necessary to promote and sell the medications in Canada.  

TWYNEO, which the FDA has approved for treating acne vulgaris in adults and paediatric patients nine years of age and older, and EPSOLAY, which the FDA has approved for treating inflammatory lesions of rosacea in adults, are products of Sol-Gel. Galderma is the only licence holder and distributor of both medications in the United States.

The above information focuses are simply identified with the organizations' center identified with sol-gel coatings market growth.

• 
  

  Akzo Nobel NV

  
  


• 
  

  SCHOTT

  
  


• 
  

  3M

  
  


• 
  

  PPG Industries

  
  


• 
  

  3M

  
  


• 
  

  PPG Industries, Inc.